Darío Ramis

Dr. Darío Ramis

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ARAlejandro Rodríguez-Vázquez
Alejandro Rodríguez-Vázquez
SRSalvatore Rudilosso
Salvatore Rudilosso
ADAntonio Doncel-Moriano
Antonio Doncel-Moriano
ACAndrea Cabero-Arnold
Andrea Cabero-Arnold
CLCarlos Laredo
Carlos Laredo
ÁCÁngel Chamorro
Ángel Chamorro
Malignant cerebral infarction (MCI) is rare but often fatal. Early identification helps guide monitoring and decompressive surgery. This study evaluated whether serum biomarkers add predictive value beyond clinical and imaging data in severe stroke patients with anterior circulation large vessel occlusion (LVO). In this prospective study, 73 acute severe LVO stroke patients underwent whole-brain CT perfusion (CTP) with rCBV-based core measurement at admission and follow-up MRI at 24 ± 12 h for infarct and edema volume assessment. Serum biomarkers (s100b, NSE, VEGF, ICAM1) were sampled a median of 20.5 h after baseline imaging. Logistic regression models predicted MCI using baseline variables (NIHSS, ASPECTS, rCBV < 30%), adding treatment data (rtPA, mTICI, NIHSS posttreatment), and adding serum biomarkers. Performance was assessed by AUC, accuracy, F1, and cross-validated R2. MCI occurred in 18/73 (24%) patients. Baseline models showed an AUC of 0.72; adding treatment improved the AUC to 0.88. Biomarkers slightly increased the AUC (0.90) but did not improve F1. Higher s100b was associated with more severe injury but did not enhance the prediction of MCI. Models with baseline imaging and treatment best explained infarct (R2 ≈ 0.27) and edema (R2 ≈ 0.58). In conclusion, admission severity, CTP, and early treatment response are the main predictors of MCI and aid early risk stratification of patients. Despite their pathophysiologic relevance, serum biomarkers do not add substantial predictive value.

18 May 2026 in Scientific Reports
Verified
Journal Article
Open access
DRDarío Ramis
Darío Ramis
SRSalvatore Rudilosso
Salvatore Rudilosso
AGAndres Girona
Andres Girona
OBOna Brengaret
Ona Brengaret
IRIrene Rosa-Batlle
Irene Rosa-Batlle
ACAngel Chamorro
Angel Chamorro
Circulating biomarkers reflecting inflammation and endothelial dysfunction have been proposed as indicators of cerebral small vessel disease; however, their relevance during the hyperacute phase of ischemic stroke remains uncertain. We aimed to determine whether circulating biomarkers measured on admission differ between small ischemic stroke subtypes and whether they provide prognostic information beyond conventional predictors. We conducted a retrospective analysis of 168 patients with acute ischemic stroke treated with intravenous thrombolysis within 4.5 h of onset, classified by MRI as having recent small subcortical infarcts (RSSI; n = 84) or small cortical or cortico-subcortical infarcts (non-RSSI; n = 84). We measured admission blood levels of interleukin-1β, interleukin-6, matrix metalloproteinase-9 (MMP-9), vascular cell adhesion molecule-1 (VCAM-1), neurofilament light chain (NfL), C-reactive protein (CRP), and leukocyte ratios, and evaluated their associations with 3‑month functional outcomes using the modified Rankin Scale. Our findings showed that RSSI patients were younger (66 vs. 74 years, p < 0.001) and had smaller infarcts (0.68 vs. 2.55 mL, p < 0.001). Higher NfL (OR 2.07, p < 0.001) and VCAM‑1 levels (OR 1.84, p = 0.034) were associated with poorer outcomes. Notably, the prognostic contribution of CRP, MMP‑9, and VCAM‑1 was more pronounced in patients with RSSI. These findings suggest that circulating biomarkers may offer additional prognostic value, with patterns varying across small ischemic stroke subtypes, though their clinical utility warrants further investigation.